Shop Now
Express shipping

Available Australia wide

99%+ PURITY

Lab Verified

Lab Tested in USA

GMP Certified

| |

Tirzepatide

Dual GIP + GLP-1 Agonist | Enhanced Fat Loss & Appetite Control
  • Third-party tested (independent lab)
  • ≥99% purity (HPLC / MS verified)
  • Batch verification documentation
  • Shipped from Australia

Price range: $190.95 through $279.95

Shipping calculated at checkout

Recommended with this product
Recommended with this product
Product total
Options total
Grand total
This product is intended for laboratory research use only. Not for human consumption.

Dosage
20-40MG per vial
Express Delivery
24 Hour from Perth
Categories
, ,
Research Dosage
2.5mg to 15mg once weekly / 8 to 24 weeks
DELIVERY FROM PERTH WAREHOUSE - SAME DAY DISPATCH

Note: BAC Water is required for reconstitution with all research peptides

  • Same Day Processing & Dispatch
  • Third-Party Tested
  • Batch Verified
  • Scientifically Transparent
  • Same Day Processing & Dispatch
  • Third-Party Tested
  • Batch Verified
  • Scientifically Transparent

What is Tirzepatide

TIRZEP, aka Tirzepatide, is a dual GIP and GLP-1 receptor agonist originally developed for type 2 diabetes management. It has gained significant attention for its potent effects on weight loss, appetite regulation, and metabolic function. Unlike traditional GLP-1 agonists, Tirzepatide activates two incretin pathways, contributing to stronger glycaemic control and fat reduction. Athletes and bodybuilders also research it during recomposition or contest prep for its appetite-blunting and fat-shredding potential.

Benefits of Tirzepatide

  • Powerful appetite suppression and satiety support
  • Rapid and sustained weight and fat loss
  • Improves insulin sensitivity and blood glucose control
  • Enhances metabolic rate and energy utilization
  • May support cardiovascular and liver health

Research Applications

Weight Loss & Appetite Regulation Research

Tirzepatide is studied for:

  • Appetite signaling and satiety mechanisms
  • Sustainable fat loss models and energy intake reduction
  • Bodyweight reduction pathways through dual incretin activation

Glycaemic Control & Insulin Sensitivity

Researchers observe:

  • Improvements in insulin response and glucose metabolism
  • Glycaemic performance in metabolic disorder models
  • Interaction between GIP + GLP-1 pathways in blood sugar regulation

Metabolic Performance & Recomposition Support

Laboratory studies explore:

  • Fat reduction with lean tissue support in calorie deficit models
  • Metabolic efficiency and energy utilization improvements
  • Cardiovascular and liver health markers during weight reduction research

Previous Research Dosages Used

Doses range from 2.5mg to 15mg once weekly in clinical trials, gradually increased to mitigate side effects. Studies typically span 8 to 24 weeks or longer, assessing fat loss, glycaemic control, and metabolic performance.

Certificate of Analysis

Chemical Structure

Tirzepatide is a modified peptide engineered to act as a dual agonist of the GIP and GLP-1 receptors. Its molecular design supports extended activity through structural modifications, enabling once-weekly administration in research settings.
Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight 4813.45 g/mol
Purity≥99%
AppearanceWhite Lyophilized Powder
StorageStore at -20°C
FormLyophilized Peptide Powder

Key Structural Characteristics

  • Dual incretin activation (GIP + GLP-1) through peptide-based receptor binding
  • Modified structure supports prolonged activity and weekly dosing
  • Frequently used in metabolic, obesity, and glycaemic regulation research